Objective To investigate the differential expression of microRNAs (miRNAs) in multiple myeloma (MM) and analyze the expression of hsa-miR-3937 in patients' peripheral blood and its potential clinical utility. Methods In this study, differential miRNAs expression in MM patients' plasma was screened using an open dataset from the GEO database and validated by real-time fluorescence quantitative PCR for differences in miRNAs expression between MM patients' plasma and healthy controls. Sensitivity and specificity of hsa-miR-3937 in MM diagnosis were analyzed using the subjects' working characteristic curve (ROC) and the association of hsa-miR-3937 in MM patient plasma with various clinical indicators was analyzed by Spearman method to evaluate its potential clinical utility. Results Expression of hsa-miR-3937 significantly upregulated in MM patients compared to healthy controls (P<0.01). The area under the ROC curve of hsa-miR-3937 showed high sensitivity and specificity in the diagnosis of MM. We also found that the expression of hsa-miR-3937 was highly correlated with the expression of serum M protein and bone marrow plasma cell, which is expected to be a potential novel biomarker for the diagnosis of MM patients. Conclusion The experimental data show that hsa-miR-3937 is highly specific in the plasma of MM patients, which has high sensitivity and specificity as a new clinical diagnostic marker, and is expected to become a potential new clinical diagnostic molecular marker.